Article
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
All News
Article
A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.
Dr. John Cush
Tweet
Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/DlKs3DGWNu https://t.co/M7qrcfcE2y
Dr. John Cush
Tweet
Study of 78 pt suspected of #GCA undergoing Temp. artery Bx and US. Nearly half (35) Dx w/ GCA. Both had similar sensitivities(69% and 63%, respectively), but specificity higher w/ biopsy (100% vs 79%). Compression sign had best diagnostic performance https://t.co/wzVqrHvfqM https://t.co/HRmfb6g7aF
Dr. John Cush
Tweet
Dr. John Cush
Tweet
Phase 3 Trials of Baricitinib Disappoint in SL
Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE.
https://t.co/SwU7ujZnsP https://t.co/IgpCTtyDNA
Dr. John Cush
Tweet
While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/nhqg0ky7RT https://t.co/kBuqvJYFYE
Dr. John Cush
Tweet
"My eye is swollen": an underrecognized mimic of IgG4-related disease
Artem Minalyan, MD, presenting his poster at RWCS 2023.
https://t.co/N2VShY5OHY https://t.co/fQYbFH6Mnb
Dr. John Cush
Tweet
Treat-to-Target Guidelines for GCA and PMR
The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
https://t.co/zb0PXsW5mw https://t.co/PdFd9A794O
Dr. John Cush
Tweet
FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/7GHG2uG9yQ https://t.co/MZ7RYGdDfG
Dr. John Cush
Tweet
Triad of Trouble: A case of joint, skin and GI woes
Sara Faghihi Kashani, MD, presents her poster at RWCS 2023
https://t.co/xwT2jV1gJv https://t.co/g63tRHsoQY
Dr. John Cush
Tweet
Sarilumab is FDA Approved for PMR
The FDA approved sarilumab for PMR, stipulating it is indicated in those patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
https://t.co/VjzloCbpBv https://t.co/9dVb6sVbph
Dr. John Cush
Tweet
"My eye is swollen": an underrecognized mimic of IgG4-related disease
Artem Minalyan, MD, presenting his poster at RWCS 2023.
https://t.co/1j3FMazdyk https://t.co/K7VoQHhhGz
Dr. John Cush
Tweet
Without head-to-head trials, do we look to metanalyses? 13 trials of TNF inhibitors in JIA pts - Results at 12-14 weeks. While it ADA looks possibly better, that would be an over-interpretation and misuse of trial data that isnt truly comparable https://t.co/k6QcPZZj67 https://t.co/SwwND1VFfT
Dr. John Cush
Tweet
51 Juvenile SLE (j-SLE) studied for neuropsychiatric Dz (j-NPSLE)- 39% presented with jNPSLE. While no clear biomarker/imaging of j-NPSLE identified, they found CSF neopterin (& IFN-α) levels signif higher w/ active j-NPSLE & CNS involvement (p=0.0008) https://t.co/QM8yJGrBJu https://t.co/4hj1eE2JIC
Dr. John Cush
Tweet
Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP findings were mainly onycholysis in79% and nail pitting in 70% https://t.co/2NynITxe6B https://t.co/qs4uYySjxp
Dr. John Cush
Tweet
Mycobacterium Tuberculosis Osteomyelitis in a Patient on Pembrolizumab
Jourdan Frankovich, MD, presents her poster at RWCS 2023.
https://t.co/198oMm7GRa https://t.co/Qnh1sOOl6s
Dr. John Cush
Tweet
PsA: Depressing News on Second- and Later-Line Treatments
Most patients with PsA failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.
https://t.co/7tSzoNLVoD https://t.co/3oUM4E38b1
Dr. John Cush
Tweet
Treat-to-Target Guidelines for GCA and PMR
The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
https://t.co/OQmtqGGNQu https://t.co/eEOTWfdgLI
Dr. John Cush
Tweet
Prospective study of 490 mod-to-severe psoriasis compared prospectively by exam & US for PsA - 384 w/o arthritis (Silent PSO), 80 non-PSO & 106 w prodromal or active PsA (12.7%). US synovio-enthesitis in 1.8% of controls & 16.1% of silent PSO (p< 0.001) https://t.co/kUdIwLnfYL https://t.co/dgIaOXaJKR
